Rapamycin formulation using recombinant high-density lipoprotein including apolipoprotein a-i and a mutant thereof
AssigneeIndustry-Academic Cooperation Foundation, Yeungnam University
InventorKyung-Hyun Cho
Life of this patent
Estimating the term…
Abstract
Provided is a rapamycin formulation using a recombinant high-density lipoprotein including apolipoprotein mutant, the rapamycin formulation in which solubility of rapamycin and medical use, such as aging suppression and arteriosclerosis suppression, are improved by using recombinant high-density lipoprotein including apolipoprotein A-I and its mutant V156K.
Claims7
1-6. (canceled)
A rapamycin formulation comprising rapamycin in an amount of 0.1 to 10 parts by weight based on a total 100 parts by weight of a recombinant high-density lipoprotein, wherein the recombinant high-density lipoprotein includes wild type apolipoprotein A-I or its mutant V156K that is prepared by substituting an amino acid at the location of No. 156 of apolipoprotein (apoA-I) with lysine.
A method of preparing rapamycin formulation, comprising:
- preparing any one selected from wild type apolipoprotein A-I or its mutant V156K that is prepared by substituting an amino acid at the location of No. 156 of apolipoprotein (apoA-I) with lysine;
- mixing any one selected from wild type apolipoprotein A-I or its mutant V156K with phospholipid, cholesterol, and sodium cholate to prepare recombinant high-density lipoprotein;
- and
- adding rapamycin to the recombinant high-density lipoprotein.
Dependencies are inferred from the claim text.